Vanguard Group Inc. Lowers Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Vanguard Group Inc. trimmed its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,010,544 shares of the biopharmaceutical company's stock after selling 41,145 shares during the period. Vanguard Group Inc. owned 4.09% of Theravance Biopharma worth $18,919,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Barclays PLC lifted its stake in Theravance Biopharma by 279.9% in the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company's stock valued at $529,000 after buying an additional 48,316 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Theravance Biopharma during the third quarter valued at approximately $251,000. Magnetar Financial LLC lifted its position in shares of Theravance Biopharma by 125.8% in the fourth quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock valued at $259,000 after acquiring an additional 15,328 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Theravance Biopharma in the fourth quarter worth approximately $103,000. Finally, American Century Companies Inc. raised its stake in Theravance Biopharma by 11.9% in the 4th quarter. American Century Companies Inc. now owns 77,931 shares of the biopharmaceutical company's stock valued at $733,000 after purchasing an additional 8,289 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Theravance Biopharma Stock Up 2.0 %

Shares of Theravance Biopharma stock traded up $0.18 on Tuesday, hitting $9.31. 217,628 shares of the company were exchanged, compared to its average volume of 282,434. The company has a 50-day moving average price of $9.10 and a 200 day moving average price of $9.17. The stock has a market capitalization of $465.51 million, a price-to-earnings ratio of -9.22 and a beta of 0.14. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $10.90.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). The company had revenue of $18.75 million during the quarter, compared to analyst estimates of $29.90 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. Research analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $11.33.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.